Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  210.12
+2.20 (1.06%)
AAPL  263.58
-9.37 (-3.43%)
AMD  200.28
-3.41 (-1.67%)
BAC  49.73
-2.57 (-4.92%)
GOOG  311.72
+4.57 (1.49%)
META  648.76
-8.25 (-1.25%)
MSFT  393.06
-8.67 (-2.16%)
NVDA  176.60
-8.29 (-4.48%)
ORCL  145.20
-5.11 (-3.40%)
TSLA  402.52
-6.06 (-1.48%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.